U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 1639

1.
Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response
Cecília Monteiro, Jaleh S. Mesgarzadeh, João Anselmo, Joana Fernandes, Marta Novais, Carla Rodrigues, David L. Powers, Evan T. Powers, Teresa Coelho, Jeffery W. Kelly
Amyloid. Author manuscript; available in PMC 2024 Mar 1.
Published in final edited form as: Amyloid. 2023 Mar; 30(1): 81–95. Published online 2022 Sep 30. doi: 10.1080/13506129.2022.2126308
PMCID:
PMC9992127
ArticlePDF–1.5M
2.
Cerebrospinal Fluid and Vitreous Body Exposure to Orally Administered Tafamidis in hereditary ATTRV30M (p.TTRV50M) Amyloidosis Patients
Cecilia Monteiro, Ana Martins da Silva, Natália Ferreira, Jaleh Mesgarzadeh, Marta Novais, Teresa Coelho, Jeffery W. Kelly
Amyloid. Author manuscript; available in PMC 2019 Jul 11.
Published in final edited form as: Amyloid. 2018 Jun; 25(2): 120–128. Published online 2018 Jul 11. doi: 10.1080/13506129.2018.1479249
PMCID:
PMC6177313
ArticlePDF–735K
3.
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
Thibaud Damy, Pablo Garcia‐Pavia, Mazen Hanna, Daniel P. Judge, Giampaolo Merlini, Balarama Gundapaneni, Terrell A. Patterson, Steven Riley, Jeffrey H. Schwartz, Marla B. Sultan, Ronald Witteles
Eur J Heart Fail. 2021 Feb; 23(2): 277–285. Published online 2020 Nov 12. doi: 10.1002/ejhf.2027
PMCID:
PMC8048553
ArticlePDF–353K
4.
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
Perry Elliott, Brian M. Drachman, Stephen S. Gottlieb, James E. Hoffman, Scott L. Hummel, Daniel J. Lenihan, Ben Ebede, Balarama Gundapaneni, Benjamin Li, Marla B. Sultan, Sanjiv J. Shah
Circ Heart Fail. 2022 Jan; 15(1): e008193. Published online 2021 Dec 20. doi: 10.1161/CIRCHEARTFAILURE.120.008193
PMCID:
PMC8763250
ArticlePDF–391K
5.
Predictive model of response to tafamidis in hereditary ATTR polyneuropathy
Cecília Monteiro, Jaleh S. Mesgazardeh, João Anselmo, Joana Fernandes, Marta Novais, Carla Rodrigues, Gabriel J. Brighty, David L. Powers, Evan T. Powers, Teresa Coelho, Jeffery W. Kelly
JCI Insight. 2019 Jun 20; 4(12): e126526. Published online 2019 Jun 20. doi: 10.1172/jci.insight.126526
PMCID:
PMC6629131
ArticlePDF–2.4M
6.
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort
Anuja Roy, Andrew Peterson, Nick Marchant, Jose Alvir, Rahul Bhambri, Zach Bredl, Darrin Benjumea, Jason Kemner, Bhash Parasuraman
J Manag Care Spec Pharm. 2022 Jul; 28(7): 10.18553/jmcp.2022.28.7.766. doi: 10.18553/jmcp.2022.28.7.766
PMCID:
PMC10372989
ArticlePDF–295K
7.
Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
Márcia Waddington Cruz
Clin Auton Res. 2019; 29(Suppl 1): 19–24. Published online 2019 Aug 12. doi: 10.1007/s10286-019-00625-9
PMCID:
PMC6763524
ArticlePDF–322K
8.
Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study
Cheng-Hsuan Tsai, Chi-Chao Chao, Sung-Tsang Hsieh, An-Li Yu, Yuan-Kun (Aden) Wu, Mei-Fang Cheng, Ming-Jen Lee, Chia-Hung Chou, Chia-Tung Shun, Hsueh-Wen Hsueh, Jimmy Jyh-Ming Juang, Ping-Huei Tseng, Mao-Yuan Su, Yen-Hung Lin
Orphanet J Rare Dis. 2023; 18: 289. Published online 2023 Sep 13. doi: 10.1186/s13023-023-02824-0
PMCID:
PMC10498629
ArticlePDF–1.3M
9.
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
Mark H Rozenbaum, Andrea Garcia, Daniel Grima, Diana Tran, Rahul Bhambri, Michelle Stewart, Benjamin Li, Bart Heeg, Maarten Postma, Ahmad Masri
Eur Heart J Qual Care Clin Outcomes. 2022 Sep; 8(5): 529–538. Published online 2021 Apr 24. doi: 10.1093/ehjqcco/qcab031
PMCID:
PMC9382662
ArticlePDF–1.4M
10.
Personalized Medicine Approach for Optimizing the Dose of Tafamidis to Potentially Ameliorate Wild-type Transthyretin Amyloidosis (Cardiomyopathy)
Younhee Cho, Aleksandra Baranczak, Stephen Helmke, Sergio Teruya, Evelyn M. Horn, Mathew S. Maurer, Jeffery W. Kelly
Amyloid. Author manuscript; available in PMC 2016 Sep 1.
Published in final edited form as: Amyloid. 2015 Sep; 22(3): 175–180. Published online 2015 Jul 25. doi: 10.3109/13506129.2015.1063485
PMCID:
PMC4549186
ArticlePDF–436K
11.
Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
René Rettl, Tim Wollenweber, Franz Duca, Christina Binder, Bernhard Cherouny, Theresa-Marie Dachs, Luciana Camuz Ligios, Lore Schrutka, Daniel Dalos, Dietrich Beitzke, Christian Loewe, Roza Badr Eslam, Johannes Kastner, Marcus Hacker, Diana Bonderman
Eur Heart J Cardiovasc Imaging. 2023 Aug; 24(8): 1019–1030. Published online 2023 Mar 7. doi: 10.1093/ehjci/jead030
PMCID:
PMC10364619
ArticlePDF–6.4M
12.
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Christine E. Bulawa, Stephen Connelly, Michael DeVit, Lan Wang, Charlotte Weigel, James A. Fleming, Jeff Packman, Evan T. Powers, R. Luke Wiseman, Theodore R. Foss, Ian A. Wilson, Jeffery W. Kelly, Richard Labaudinière
Proc Natl Acad Sci U S A. 2012 Jun 12; 109(24): 9629–9634. Published online 2012 May 29. doi: 10.1073/pnas.1121005109
PMCID:
PMC3386102
ArticlePDF–608K
13.
The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers
Peter A. Lockwood, Vu H. Le, Melissa T. O'Gorman, Terrell A. Patterson, Marla B. Sultan, Ekaterina Tankisheva, Qiang Wang, Steve Riley
Clin Pharmacol Drug Dev. 2020 Oct; 9(7): 849–854. Published online 2020 Mar 20. doi: 10.1002/cpdd.789
PMCID:
PMC7754314
ArticlePDF–204K
14.
Pharmacological treatment for familial amyloid polyneuropathy
Francesca Magrinelli, Gian Maria Fabrizi, Lucio Santoro, Fiore Manganelli, Giampietro Zanette, Tiziana Cavallaro, Stefano Tamburin, Cochrane Neuromuscular Group
Cochrane Database Syst Rev. 2020; 2020(4): CD012395. Published online 2020 Apr 20. doi: 10.1002/14651858.CD012395.pub2
PMCID:
PMC7170468
ArticlePDF–849K
15.
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Mark H. Rozenbaum, Diana Tran, Rahul Bhambri, Jose Nativi-Nicolau
Am J Cardiovasc Drugs. 2022; 22(4): 445–450. Published online 2022 Mar 30. doi: 10.1007/s40256-022-00526-9
PMCID:
PMC9270297
ArticlePDF–577K
16.
Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
Dhruv S. Kazi, Brandon K. Bellows, Suzanne J. Baron, Changyu Shen, David J. Cohen, John A. Spertus, Robert W. Yeh, Suzanne V. Arnold, Brett W. Sperry, Mathew S. Maurer, Sanjiv J. Shah
Circulation. Author manuscript; available in PMC 2021 Apr 14.
Published in final edited form as: Circulation. 2020 Apr 14; 141(15): 1214–1224. Published online 2020 Feb 12. doi: 10.1161/CIRCULATIONAHA.119.045093
PMCID:
PMC7156331
ArticlePDF–743K
17.
Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
Camille Vong, Martin Boucher, Steve Riley, Lutz O. Harnisch
Am J Cardiovasc Drugs. 2021; 21(5): 535–543. Published online 2021 Mar 26. doi: 10.1007/s40256-021-00464-y
PMCID:
PMC8435516
ArticlePDF–1.4M
18.
Biophysical characterization and modulation of Transthyretin Ala97Ser
Yo‐Tsen Liu, Yueh‐Jung Yen, Frans Ricardo, Yu Chang, Pei‐Hao Wu, Shing‐Jong Huang, Kon‐Ping Lin, Tsyr‐Yan Yu
Ann Clin Transl Neurol. 2019 Oct; 6(10): 1961–1970. Published online 2019 Sep 10. doi: 10.1002/acn3.50887
PMCID:
PMC6801203
ArticlePDF–1.3M
19.
Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
Gerard T Giblin, Sarah A M Cuddy, Esther González-López, Alanna Sewell, Amanda Murphy, Sharmila Dorbala, Rodney H Falk
Eur Heart J Cardiovasc Imaging. 2022 Aug; 23(8): 1029–1039. Published online 2022 Mar 11. doi: 10.1093/ehjci/jeac049
PMCID:
PMC9303005
ArticlePDF–1.1M
20.
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho, Luis F. Maia, Ana Martins da Silva, Márcia W. Cruz, Violaine Planté-Bordeneuve, Ole B. Suhr, Isabel Conceiçao, Hartmut H.-J. Schmidt, Pedro Trigo, Jeffery W. Kelly, Richard Labaudinière, Jason Chan, Jeff Packman, Donna R. Grogan
J Neurol. 2013; 260(11): 2802–2814. Published online 2013 Aug 22. doi: 10.1007/s00415-013-7051-7
PMCID:
PMC3825212
ArticlePDF–526K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center